ELMD vs. ZYXI, AXGN, EDAP, SMLR, OM, FONR, VANI, HYPR, CUTR, and POCI
Should you be buying Electromed stock or one of its competitors? The main competitors of Electromed include Zynex (ZYXI), AxoGen (AXGN), Edap Tms (EDAP), Semler Scientific (SMLR), Outset Medical (OM), FONAR (FONR), Vivani Medical (VANI), Hyperfine (HYPR), Cutera (CUTR), and Precision Optics (POCI). These companies are all part of the "electromedical equipment" industry.
Zynex (NASDAQ:ZYXI) and Electromed (NYSE:ELMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation, community ranking and dividends.
Zynex presently has a consensus target price of $18.00, suggesting a potential upside of 77.34%. Given Electromed's higher probable upside, research analysts clearly believe Zynex is more favorable than Electromed.
In the previous week, Zynex had 1 more articles in the media than Electromed. MarketBeat recorded 1 mentions for Zynex and 0 mentions for Electromed. Electromed's average media sentiment score of 1.44 beat Zynex's score of 0.00 indicating that Zynex is being referred to more favorably in the media.
Electromed has a net margin of 8.14% compared to Electromed's net margin of 4.33%. Electromed's return on equity of 16.34% beat Zynex's return on equity.
29.7% of Zynex shares are owned by institutional investors. Comparatively, 40.8% of Electromed shares are owned by institutional investors. 52.1% of Zynex shares are owned by company insiders. Comparatively, 12.7% of Electromed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Zynex received 9 more outperform votes than Electromed when rated by MarketBeat users. However, 86.67% of users gave Electromed an outperform vote while only 51.16% of users gave Zynex an outperform vote.
Zynex has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, Electromed has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500.
Zynex has higher revenue and earnings than Electromed. Electromed is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.
Summary
Zynex beats Electromed on 11 of the 17 factors compared between the two stocks.
Get Electromed News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Electromed Competitors List
Related Companies and Tools
